What is the recommended approach to glycemic control in hospitalized adult patients, including target glucose range and insulin regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Glycemic Control in Hospitalized Patients

For hospitalized patients with persistent hyperglycemia ≥180 mg/dL (confirmed on two occasions), initiate insulin therapy and target a glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) for both critically ill and noncritically ill patients. 1

When to Start Treatment

Start insulin therapy when blood glucose reaches ≥180 mg/dL on two separate measurements within 24 hours. 1, 2 This threshold applies universally across ICU and non-ICU settings and is based on the landmark NICE-SUGAR trial, which demonstrated that intensive glycemic control (80-110 mg/dL) resulted in 10- to 15-fold higher rates of hypoglycemia and increased mortality (27.5% vs 25%) compared to moderate targets. 1

Target Glucose Range

Standard Target (Most Patients)

  • 140-180 mg/dL (7.8-10.0 mmol/L) for both critically ill and noncritically ill patients 1, 2
  • This moderate target balances glycemic control against hypoglycemia risk, which is the primary driver of mortality in tight control strategies

More Stringent Targets (Selected Patients Only)

Consider 110-140 mg/dL (6.1-7.8 mmol/L) for: 1

  • Critically ill postsurgical patients
  • Cardiac surgery patients
  • Only if achievable without significant hypoglycemia

Alternative Target for Noncritically Ill

Expert consensus supports 100-180 mg/dL (5.6-10.0 mmol/L) for noncritically ill patients with new hyperglycemia or known diabetes. 1 Note that fasting glucose <100 mg/dL predicts hypoglycemia within 24 hours, so avoid targeting below this threshold. 1

Liberalized Targets (Special Circumstances)

  • 180-250 mg/dL: Acceptable for patients with severe comorbidities or settings with limited glucose monitoring capability 3
  • >250 mg/dL: May be acceptable in terminally ill patients with short life expectancy to minimize glucosuria and dehydration 1

Insulin Regimen Selection

Critically Ill Patients (ICU)

Use continuous intravenous insulin infusion with a standardized protocol that has demonstrated safety and efficacy. 4, 5 This is the only appropriate method for achieving glycemic targets in critically ill patients due to:

  • Rapidly changing insulin requirements
  • Need for frequent dose adjustments
  • Requirement for monitoring every 30 minutes to 2 hours

Noncritically Ill Patients

The regimen depends on oral intake and baseline glycemic control:

For patients with good nutritional intake:

  • Basal-bolus-correction insulin regimen (basal + prandial + correction components) 4
  • This is superior to sliding scale insulin alone, which is strongly discouraged 4

For patients with poor or no oral intake (NPO):

  • Basal insulin plus correction insulin only 4
  • Withhold prandial insulin when oral intake is inadequate

Dosing algorithm based on severity: 6

  • Mild hyperglycemia (<200 mg/dL), insulin-naive, or low home insulin doses:

    • Low-dose basal insulin OR DPP-4 inhibitor
    • Add correction doses with rapid-acting insulin before meals or every 6 hours

  • Moderate hyperglycemia (201-300 mg/dL) or insulin total daily dose (TDD) <0.6 U/kg/day:

    • Start basal insulin at 0.2-0.3 U/kg/day
    • Add correction doses with rapid-acting insulin

  • Severe hyperglycemia (>300 mg/dL) or home insulin TDD >0.6 U/kg/day:

    • Basal-bolus regimen: Reduce home TDD by 20% or start at 0.3 U/kg/day
    • Give half as basal, half as bolus (divided before meals)
    • Adjust as needed based on response

Glucose Monitoring

Point-of-care (POC) testing frequency: 1, 2

  • Patients eating: Before each meal
  • Patients not eating: Every 4-6 hours
  • Patients on IV insulin: Every 30 minutes to 2 hours (required standard)

Continuous glucose monitoring (CGM): 2

  • Continuation of personal CGM devices is recommended for patients with type 1 diabetes or type 2 diabetes on intensive therapy
  • Requires confirmatory POC capillary testing for insulin dosing and hypoglycemia assessment
  • Emerging evidence supports CGM use for detecting nocturnal and asymptomatic hypoglycemia

Critical Pitfalls to Avoid

  1. Never use sliding scale insulin (SSI) alone - it is strongly discouraged and associated with poor outcomes 4

  2. Avoid tight glycemic control (80-110 mg/dL) - the Van den Berghe study initially showed mortality benefit, but NICE-SUGAR definitively demonstrated increased mortality and 10-15 fold higher hypoglycemia rates with intensive control 1

  3. Do not target fasting glucose <100 mg/dL - this predicts hypoglycemia within 24 hours 1

  4. Implement a hypoglycemia management protocol - every hospital must have standardized protocols for preventing and treating hypoglycemia 4

  5. Check admission HbA1c - an HbA1c ≥6.5% suggests diabetes preceded hospitalization and helps guide discharge planning 1, 4

Rationale: Why These Targets Matter for Mortality

The evidence hierarchy is clear: the NICE-SUGAR trial (large, multicenter, randomized) trumps the earlier Van den Berghe study. Tight control kills patients through hypoglycemia. 1 The 140-180 mg/dL target represents the sweet spot where you reduce hyperglycemia-related complications (infections, poor wound healing, longer hospital stays) without inducing the life-threatening hypoglycemia that comes with aggressive control. Multiple meta-analyses confirm that mortality increases with targets below 140 mg/dL. 1

References

6
Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Related Questions

How should I manage a patient with a blood glucose of 568 mg/dL after a 12‑unit insulin dose given in the office?
A patient in an assisted living facility with a history of insulin use presents with blood glucose levels of 426 mg/dL, then 385 mg/dL after one hour, and 365 mg/dL after another hour, and is currently not on any antidiabetic medication. How should this severe hyperglycemia be managed?
What is the recommended insulin dosing for an adult with hyperglycemia (random plasma glucose ≥250 mg/dL)?
How should a patient with a random blood glucose >200 mg/dL be managed?
What is the appropriate correction (pulse) dosing of short‑acting regular insulin for a skilled‑nursing‑facility resident who is hyperglycemic after overeating, including the dose ranges for different glucose levels?
How should a patient with left renal vein compression between the aorta and spine (nutcracker syndrome) be managed?
What is the correct dosing and infusion rate for phenytoin (100 mg per 2 mL) in a 75‑kg adult?
What are the optimal strategies to reduce irritability in a patient with ADHD who is taking stimulant medication?
Is it safe for a patient to take Crestor (rosuvastatin) and Repatha (alirocumab) together, and what monitoring is required?
In a patient with persistent hypertension despite amlodipine 10 mg, losartan/hydrochlorothiazide 100/25 mg, and spironolactone 25 mg, what additional management steps can be taken?
What is the appropriate evaluation and management for bilateral ear pain lasting two months that began after a recent tonsillitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.